The memorial delirium assessment scale
…, B Rosenfeld, A Roth, MJ Smith, K Cohen… - Journal of pain and …, 1997 - Elsevier
We conducted two studies with medically hospitalized cancer and acquired immunodeficiency
syndrome (AIDS) patients to assess the reliability and validity of a new measure of …
syndrome (AIDS) patients to assess the reliability and validity of a new measure of …
Outpatient metformin use is associated with reduced severity of COVID‐19 disease in adults with overweight or obesity
Observational studies suggest outpatient metformin use is associated with reduced mortality
from coronavirus disease‐2019 (COVID‐19). Metformin is known to decrease interleukin‐6 …
from coronavirus disease‐2019 (COVID‐19). Metformin is known to decrease interleukin‐6 …
Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study
…, KG Jubilo, J Samranvedhya, M Lipsitch, K Cohen - Bmj, 2021 - bmj.com
Objective To evaluate the excess risk and relative hazards for developing incident clinical
sequelae after the acute phase of SARS-CoV-2 infection in adults aged 18-65. Design …
sequelae after the acute phase of SARS-CoV-2 infection in adults aged 18-65. Design …
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of
human tumors are not known. Here we show here that a single infusion of the VEGF-specific …
human tumors are not known. Here we show here that a single infusion of the VEGF-specific …
Long-term outcomes in use of opioids, nonpharmacologic pain interventions, and total costs of spinal cord stimulators compared with conventional medical therapy for …
…, PE Morin, DL Spencer, RF Redberg, K Cohen - JAMA …, 2023 - jamanetwork.com
Importance Spinal cord stimulators (SCSs) are increasingly used for the treatment of chronic
pain. There is a need for studies with long-term follow-up. Objective To determine the …
pain. There is a need for studies with long-term follow-up. Objective To determine the …
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
…, RS Call, R Canadas, LB Chaykin, K Cohen… - The Lancet, 2017 - thelancet.com
Background Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In …
[BOOK][B] The way of qigong: The art and science of Chinese energy healing
KS Cohen - 1999 - books.google.com
… "Ken Cohen is a rare combination of expert practitioner, gifted scholar, and lucid writer. He
… For those interested in optimal health, Ken Cohen's book allows you an opportunity not only …
… For those interested in optimal health, Ken Cohen's book allows you an opportunity not only …
[HTML][HTML] Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind …
…, JM Nicklas, MA Puskarich, K Cohen… - The Lancet Infectious …, 2023 - thelancet.com
Background Post-COVID-19 condition (also known as long COVID) is an emerging chronic
illness potentially affecting millions of people. We aimed to evaluate whether outpatient …
illness potentially affecting millions of people. We aimed to evaluate whether outpatient …
[PDF][PDF] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
…, E di Tomaso, WT Zhang, DG Duda, KS Cohen… - Cancer cell, 2007 - cell.com
Using MRI techniques, we show here that normalization of tumor vessels in recurrent
glioblastoma patients by daily administration of AZD2171—an oral tyrosine kinase inhibitor of …
glioblastoma patients by daily administration of AZD2171—an oral tyrosine kinase inhibitor of …
[HTML][HTML] Phase II study of cediranib, an oral pan–vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
…, T Benner, DN Louis, KS Cohen… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Glioblastoma is an incurable solid tumor characterized by increased expression of
vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in …
vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in …